World's Best Scientists 2026 revealed!
Michael W. Deininger

Michael W. Deininger

D-Index & Metrics

Medicine

D-Index
113
Citations
71290
World Ranking
4837
National Ranking
2619

Michael W. Deininger publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael W. Deininger sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 660 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael W. Deininger D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael W. Deininger sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 113 D-Index — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael W. Deininger is affiliated with the University of Utah in the United States and has made substantial contributions to the field of medicine, particularly in hematology. Their research spans multiple subfields including hematology, genetics, rheumatology, immunology, and molecular biology.

The scientist's primary research topics include chronic myeloid leukemia treatments and chronic lymphocytic leukemia research. Their work also covers eosinophilic disorders and syndromes, mast cells and histamine, acute myeloid leukemia research, acute lymphoblastic leukemia research, as well as click chemistry and its applications.

Their notable recent papers include:

  • Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology (2020), Journal of the National Comprehensive Cancer Network
  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020), Leukemia
  • Integrative analysis of drug response and clinical outcome in acute myeloid leukemia (2022), Cancer Cell
  • Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions (2021), Blood Reviews
  • Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial (2020), Nature Medicine

Frequent coauthors collaborating with Michael W. Deininger include Jorge E. Cortés, Michael J. Mauro, Daniel J. DeAngelo, Andreas Hochhaus, and Jason Gotlib. These collaborations reflect a strong network within the hematology research community.

The venues in which they regularly publish research include Blood, Clinical Lymphoma Myeloma & Leukemia, Leukemia, Journal of Clinical Oncology, and HemaSphere. This demonstrates an engagement with leading journals dedicated to hematology and oncology research.

Best Publications

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • The molecular biology of chronic myeloid leukemia

    Michael W. N. Deininger;John M. Goldman;Junia V. Melo

  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • The development of imatinib as a therapeutic agent for chronic myeloid leukemia

    Michael Deininger;Elisabeth Buchdunger;Elisabeth Buchdunger;Elisabeth Buchdunger;Brian J. Druker;Brian J. Druker;Brian J. Druker

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

    Thomas O'Hare;Thomas O'Hare;William C. Shakespeare;Xiaotian Zhu;Christopher A. Eide;Christopher A. Eide

  • In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

    Thomas O'Hare;Denise K. Walters;Eric P. Stoffregen;Taiping Jia

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

  • Functional genomic landscape of acute myeloid leukaemia

    Jeffrey W. Tyner;Cristina E. Tognon;Cristina E. Tognon;Daniel Bottomly;Beth Wilmot

  • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

    Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford

  • Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

    François Xavier Mahon;Michael W. N. Deininger;Beate Schultheis;Jérome Chabrol

  • Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

    Amie S. Corbin;Amie S. Corbin;Anupriya Agarwal;Marc Loriaux;Jorge Cortes

  • The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells

    Michael W.N. Deininger;John M. Goldman;Nicholas Lydon;Junia V. Melo

  • Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    Jorge E Cortes;Hagop M Kantarjian;Neil P. Shah;Dale Bixby

Frequent Co-Authors

Brian J. Druker
Brian J. Druker Oregon Health & Science University
Jorge E. Cortes
Jorge E. Cortes Augusta University
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Neil P. Shah
Neil P. Shah University of California, San Francisco
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Michele Baccarani
Michele Baccarani University of Bologna
Francois Guilhot
Francois Guilhot Grenoble Alpes University
Carlo Gambacorti-Passerini
Carlo Gambacorti-Passerini University of Milano-Bicocca

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA isn't limited to becoming a doctor. There are diverse, flexible pathways available, including online degrees and alternative healthcare roles. For example, those with a non-nursing background interested in advanced nursing may consider online direct entry msn programs. These accelerated options let you transition into nursing at a higher level with efficiency.

If you’re seeking a more accessible start, researching the easiest rn program could help you enter the nursing profession with less competitive barriers. Some prospective nurses may prefer institutions that simplify admissions—schools where you can find a nursing school no entrance exam policy, removing the need for lengthy standardized tests.

The healthcare field also offers vital non-clinical roles. Interested in the administrative side? Consider training through medical billing and coding schools that accept financial aid, which help support hospitals and clinics behind the scenes. Each of these pathways provides valuable alternatives for individuals passionate about making a difference in healthcare.

Best Scientists Citing Michael W. Deininger

Trending Scientists

Recently Published Articles